Intensive Care Medicine

, Volume 41, Issue 12, pp 2057–2075 | Cite as

Task force on management and prevention of Acinetobacter baumannii infections in the ICU

  • José Garnacho-Montero
  • George Dimopoulos
  • Garyphallia Poulakou
  • Murat Akova
  • José Miguel Cisneros
  • Jan De Waele
  • Nicola Petrosillo
  • Harald Seifert
  • Jean François Timsit
  • Jordi Vila
  • Jean-Ralph Zahar
  • Matteo Bassetti
Conference Reports and Expert Panel



Acinetobacter baumannii constitutes a dreadful problem in many ICUs worldwide. The very limited therapeutic options available for these organisms are a matter of great concern. No specific guidelines exist addressing the prevention and management of A. baumannii infections in the critical care setting.


Clinical microbiologists, infectious disease specialists and intensive care physicians were invited by the Chair of the Infection Section of the ESICM to participate in a multidisciplinary expert panel. After the selection of clinically relevant questions, this document provides recommendations about the use of microbiological techniques for identification of A. baumannii in clinical laboratories, antibiotic therapy for severe infections and recommendations to control this pathogen in outbreaks and endemic situations. Evidence supporting each statement was graded according to the European Society of Clinical Microbiology and Infection Diseases (ESCMID) grading system.


Empirical coverage of A. baumannii is recommended in severe infections (severe sepsis or septic shock) occurring during an A. baumannii outbreak, in an endemic setting, or in a previously colonized patient. For these cases, a polymyxin is suggested as part of the empirical treatment in cases of a high suspicion of a carbapenem-resistant (CR) A. baumannii strain. An institutional program including staff education, promotion of hand hygiene, strict contact and isolation precautions, environmental cleaning, targeted active surveillance, and antimicrobial stewardship should be instituted and maintained to combat outbreaks and endemic situations.


Specific recommendations about prevention and management of A. baumannii infections in the ICU were elaborated by this multidisciplinary panel. The paucity of randomized controlled trials is noteworthy, so these recommendations are mainly based on observational studies and pharmacodynamics modeling.


Acinetobacter baumannii Epidemiology Treatment Colistin Prevention 


Compliance with ethical standards

Conflicts of interest

JGM serves on scientific advisory board for Pfizer and declares speaker honoraria from Pfizer, Gilead Sciences, Astellas Pharma and MSD. JGM has received scientific unrestricted grants from Astellas Pharma. HS declares financial relationships with Astellas, AstraZeneca, Basilea, Cubist, Durata, FabPharma, Gilead, MSD, Novartis, Pfizer, Roche, Tetraphase, The Medicines Company and Theravance. MA declares travel and speaker honoraria from Merck, Pfizer, Astellas, Gilead Sciences and Cubist. JMC declares has received travels and honoraria as speaker from Astellas Pharma, Novartis, Pfizer, MSD and Astra-Zeneca. JDW declares consultancy for Acelity, AtoxBio, Bayer Healthcare, Cubist, Smith&Nephew, Sumitomo Pharmaceuticals. NP has served on scientific advisory boards for MSD, Pfizer, Cepheid; has received funding for travel or speaker honoraria from MSD, Novartis, Gilead, Pfizer, Zambon, Angelini, Achaogen, Johnson & Johnson. JFT serves on scientific advisory board for Bayer, Merck, 3 M. JFT received scientific unrestricted grants from Merck, Astellas, 3 M, Pfizer. JFT declares travel or speaker honoraria from Merck, Gilead, Astellas, 3 M, Bayer. NP has served on scientific advisory boards for MSD, Pfizer, Cepheid, The Medicines Company; has received funding for travel or speaker honoraria from MSD, Novartis, Gilead, Pfizer, Zambon, Angelini, Achaogen, Johnson & Johnson, Astellas, Carefusion. JRZ declares travels and honoraria as speaker from MSD and Pfizer. MB serves on scientific advisory boards for AstraZeneca, Bayer, Cubist, Pfizer Inc, MSD, Tetraphase and Astellas Pharma Inc, funding for travel or speaker honoraria from Algorithm, Angelini, Astellas Pharma Inc., AstraZeneca, Cubist, Pfizer MSD, Gilead Sciences, Novartis, Ranbaxy, Teva. The other authors have not declared any conflict of interest regarding this manuscript.

Supplementary material

134_2015_4079_MOESM1_ESM.doc (88 kb)
Supplementary material 1 (DOC 87 kb)


  1. 1.
    Dijkshoorn L, Nemec A, Seifert H (2007) An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5:939–951PubMedCrossRefGoogle Scholar
  2. 2.
    Garnacho-Montero J, Amaya-Villar R (2010) Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 23:332–339PubMedCrossRefGoogle Scholar
  3. 3.
    Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y (2009) Reinhart K; EPIC II group of investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329PubMedCrossRefGoogle Scholar
  4. 4.
    Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, Diaz E, Topeli A, DeWaele J, Carneiro A, Martin-Loeches I, Armaganidis A, Rello J, EU-VAP/CAP Study Group (2009) Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 37:2360–2368PubMedCrossRefGoogle Scholar
  5. 5.
    Tabah A, Koulenti D, Laupland K, Misset B, Valles J, de Carvalho FB, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF (2012) Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 38:1930–1945PubMedCrossRefGoogle Scholar
  6. 6.
    Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, Wenzel RP, Seifert H (2012) Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 64:282–290PubMedCrossRefGoogle Scholar
  7. 7.
    Roca I, Mosqueda N, Altun B, Espinal P, Akova M, Vila J (2014) Molecular characterization of NDM-1-producing Acinetobacter pittii isolated from Turkey in 2006. J Antimicrob Chemother 69:3437–3438PubMedCrossRefGoogle Scholar
  8. 8.
    Zander E, Fernández-González A, Schleicher X, Dammhayn C, Kamolvit W, Seifert H, Higgins PG (2014) Worldwide dissemination of acquired carbapenem-hydrolysing class D β-lactamases in Acinetobacter spp. other than Acinetobacter baumannii. Int J Antimicrob Agents 43:375–377PubMedCrossRefGoogle Scholar
  9. 9.
    Peleg AY, Seifert H, Paterson DL (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Espinal P, Seifert H, Dijkshoorn L, Vila J, Roca I (2012) Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS. Clin Microbiol Infect 18:1097–1103PubMedCrossRefGoogle Scholar
  11. 11.
    Li J, Rayner CR, Nation RL et al (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946–2950PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Pournaras S, Ikonomidis A, Markogiannakis A, Maniatis AN, Tsakris A (2005) Heteroresistance to carbapenems in Acinetobacter baumannii. J Antimicrob Chemother 55:1055–1056PubMedCrossRefGoogle Scholar
  13. 13.
    Herrera ME, Mobilia LN, Posse GR (2011) Comparative evaluation of the sensitivity of Acinetobacter to colistin, using the prediffusion and minimum inhibitory concentration methods: detection of heteroresistant isolates. Rev Argent Microbiol 43:115–119PubMedGoogle Scholar
  14. 14.
    Rodriguez CH, De Ambrosio A, Bajuk M et al (2010) In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 4:164–167PubMedCrossRefGoogle Scholar
  15. 15.
    Rodriguez CH, Bombicino K, Granados G et al (2009) Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 65:188–191PubMedCrossRefGoogle Scholar
  16. 16.
    Hawley JS, Murray CK, Jorgensen JH (2008) Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52:351–352PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendía JL, Ortiz C, Cobacho AR (1996) Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 22:1026–1032PubMedCrossRefGoogle Scholar
  18. 18.
    Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, Garcia-Curiel A, Jiménez-Jiménez FJ (2005) Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 31:649–655PubMedCrossRefGoogle Scholar
  19. 19.
    Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L (2008) Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 3:649–660PubMedCrossRefGoogle Scholar
  20. 20.
    Gales AC, Jones RN, Sader HS (2011) Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006–2009). J Antimicrob Chemother 66:2070–2074PubMedCrossRefGoogle Scholar
  21. 21.
    Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M (2014) Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 78:429–436PubMedCrossRefGoogle Scholar
  22. 22.
    Fernández-Cuenca F, Tomás-Carmona M, Caballero-Moyano F, Bou G, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Pascual A (2013) In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin 31:4–9PubMedCrossRefGoogle Scholar
  23. 23.
    Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW, Lau YJ, Wang LH, Liu KS, Tsai TY, Lin SY, Hsu MS, Hsu LY, Chang SC (2010) A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis. 14:e764–e769PubMedCrossRefGoogle Scholar
  24. 24.
    Lee HY, Chen CL, Wu SR, Huang CW, Chiu CH (2014) Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med 42:1081–1088PubMedCrossRefGoogle Scholar
  25. 25.
    D'Agata EM, Thayer V, Schaffner W (2000) An outbreak of Acinetobacter baumannii: the importance of cross-transmission. Infect Control Hosp Epidemiol 21:588–591PubMedCrossRefGoogle Scholar
  26. 26.
    Arvaniti K, Lathyris D, Ruimy R, Haidich AB, Koulourida V, Nikolaidis P, Matamis D, Miyakis S (2012) The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit. Crit Care 16(3):R102PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F (2000) Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38:4086–4095PubMedCentralPubMedGoogle Scholar
  28. 28.
    Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, Chaudary K, Lephart P, Slim J, Hothi J, Ahmed H, Pogue JM, Zhao JJ, Kaye KS (2013) Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother 57:6270–6275PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M (2013) Pharmacodynamics modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother 57:3441–3444PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, Rahal JJ (1993) Effect of sulbactam on infections caused by imipenem resistant acinetobacter calcoaceticus biotype anitratus. J Infect Dis 167(448):51Google Scholar
  31. 31.
    Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA (2002) Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 34:1425–1430PubMedCrossRefGoogle Scholar
  32. 32.
    Levin ASS, Levy CE, Manrique AE, Medeiros EA, Costa SF (2003) Severe Nosocomial Infections with imipenem-resistant Acinetobacter baumannii treated with Ampicillin/Sulbactam. Int J Antimicrob Agents 21:58–62PubMedCrossRefGoogle Scholar
  33. 33.
    Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS (2008) Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61:1369–1375PubMedCrossRefGoogle Scholar
  34. 34.
    Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G (2007) High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 39:38–43PubMedCrossRefGoogle Scholar
  35. 35.
    Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56:432–436PubMedCrossRefGoogle Scholar
  36. 36.
    Zalts R, Neuberger A, Hussein K, Raz-Pasteur A, Geffen Y, Mashiach T, Finkelstein R (2013) Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam. Am J Ther, Nov 20 [Epub ahead of print]Google Scholar
  37. 37.
    Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D, Leibovici L (2010) Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 65:1019–1027PubMedCrossRefGoogle Scholar
  38. 38.
    Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD (2014) Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis 58:139–141PubMedCrossRefGoogle Scholar
  39. 39.
    Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME (2010) Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 16:1230–1236PubMedCrossRefGoogle Scholar
  40. 40.
    Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M (2010) Steady-state pharmacokinetics and bronchoalveolar lavage concentration of colistin in critically ill patients after intravenous colistin methanesulfonate administration. Chest 138:1333–1339PubMedCrossRefGoogle Scholar
  41. 41.
    Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H (2009) Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with Gram-negative bacterial infections. Antimicrob Agents Chemother 53:3430–3436PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284–3294PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54:1720–1726PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE (2012) Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241–4249PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, Tsangaris I, Armaganidis A, Cars O, Giamarellou H (2013) Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 57:668–671PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Marchand S, Frat JP, Petitpas F, Lemaître F, Gobin P, Robert R, Mimoz O, Couet W (2010) Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 65:1836–1837PubMedCrossRefGoogle Scholar
  47. 47.
    Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28:1008–1111PubMedCrossRefGoogle Scholar
  48. 48.
    Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118PubMedCrossRefGoogle Scholar
  49. 49.
    Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Neves AD, Santander O, Ramos C (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058–1065PubMedCrossRefGoogle Scholar
  50. 50.
    Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M (2007) Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. Intensive Care Med 33:1162–1167PubMedCrossRefGoogle Scholar
  51. 51.
    Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J (2008) Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298–1304PubMedCrossRefGoogle Scholar
  52. 52.
    Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP (2013) Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524–531PubMedCrossRefGoogle Scholar
  53. 53.
    Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL (2013) Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300–1303PubMedCrossRefGoogle Scholar
  54. 54.
    Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP (2014) Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43:349–352PubMedCrossRefGoogle Scholar
  55. 55.
    Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY antimicrobial surveillance program, 2009–2012. Int J Antimicrob Agents 43:328–334PubMedCrossRefGoogle Scholar
  56. 56.
    Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M (2014) Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 78:429–436PubMedCrossRefGoogle Scholar
  57. 57.
    Meagher AK, Ambrose PG, Grasela TH et al (2005) Pharmacokinetic/pharmacodynamics profile for tigecycline—a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 52:165–171PubMedCrossRefGoogle Scholar
  58. 58.
    Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD (2013) Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand J Infect Dis 45:315–319PubMedCrossRefGoogle Scholar
  59. 59.
    Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H, 311 Study Group (2010) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68:140–151PubMedCrossRefGoogle Scholar
  60. 60.
    Burkhardt O, Rauch K, Kaever V et al (2009) Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 34(1):101–102PubMedCrossRefGoogle Scholar
  61. 61.
    Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57:1756–1762PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Schafer JJ, Goff DA, Stevenson KB, Mangino JE (2007) Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 27:980–987PubMedCrossRefGoogle Scholar
  63. 63.
    Gordon NC, Wareham DW (2009) A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 63:775–780PubMedCrossRefGoogle Scholar
  64. 64.
    Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA (2011) Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39:515–518PubMedCrossRefGoogle Scholar
  65. 65.
    Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD (2013) Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand J Infect Dis 45:315–319PubMedCrossRefGoogle Scholar
  66. 66.
    De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M (2014) High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 18(3):R90PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ (2007) In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60:317–322PubMedCrossRefGoogle Scholar
  68. 68.
    Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J (2010) Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1165–1172PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC (2011) Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 70:380–386PubMedCrossRefGoogle Scholar
  70. 70.
    Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J (2006) Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58:697–700PubMedCrossRefGoogle Scholar
  71. 71.
    Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, Wang LR, Ko WC (2007) Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 27:1506–1511PubMedCrossRefGoogle Scholar
  72. 72.
    Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R (2007) Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 30:537–540PubMedCrossRefGoogle Scholar
  73. 73.
    Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P (2009) In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 8:18PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Ni W, Shao X, Di X, Cui J, Wang R, Liu Y (2014) In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. doi: 10.1016/j.ijantimicag.2014.10.002 Google Scholar
  75. 75.
    Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, Venditti M, Esposito S, Nicastri E (2005) Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11:682–683PubMedCrossRefGoogle Scholar
  76. 76.
    Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M (2006) Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 53:274–278PubMedCrossRefGoogle Scholar
  77. 77.
    Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, Orengo G (2008) Bobbio Pallavicini F, Viscoli C. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61:417–420PubMedCrossRefGoogle Scholar
  78. 78.
    Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57:349–358PubMedCrossRefGoogle Scholar
  79. 79.
    Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, Kokturk F, Ornek T, Celebi G (2013) Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141:1214–1222PubMedCrossRefGoogle Scholar
  80. 80.
    Al-Shaer M, Nazer LH, Kherallah M (2014) Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii. Ann Pharmacother 48:766–771PubMedCrossRefGoogle Scholar
  81. 81.
    Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H (2014) Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 33:1311–1322PubMedCrossRefGoogle Scholar
  82. 82.
    Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A (2014) Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 43:378–382PubMedCrossRefGoogle Scholar
  83. 83.
    López-Cortés LE, Cisneros JM, Fernández-Cuenca F, Bou G, Tomás M, Garnacho-Montero J, Pascual A, Martínez-Martínez L, Vila J, Pachón J, Baño JR, GEIH/REIPI-Ab2010 Group (2014) Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 69:3119–3126PubMedCrossRefGoogle Scholar
  84. 84.
    Gordon NC, Png K, Wareham DW (2010) Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 54:5316–5322PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Wareham DW, Gordon NC, Hornsey M (2011) In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 66:1047–1051PubMedCrossRefGoogle Scholar
  86. 86.
    Hornsey M, Longshaw C, Phee L, Wareham DW (2012) In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother 56:3080–3085PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M (2014) Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 43:370–374PubMedCrossRefGoogle Scholar
  88. 88.
    Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, de Espejo-Gutiérrez ET, Artero-González ML, Corcia-Palomo Y, Bautista-Paloma J (2013) Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant A. baumannii. Chemotherapy 59:225–231PubMedCrossRefGoogle Scholar
  89. 89.
    Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, Inkaya AC, De Pascale G, Grilli E, Tumbarello M, Akova M (2014) Colistinglycopeptide combination in critically ill patients with gram negative infection: the clinical experience. Antimicrob Agents Chemother 58:851–858PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Sirijatuphat R, Thamlikitkul V (2014) Colistin versus Colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii Infections: a preliminary study. Antimicrob Agents Chemother 58:5598–5601PubMedCentralPubMedCrossRefGoogle Scholar
  91. 91.
    Poulikakos P, Tansarli GS, Falagas ME (2014) Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33:1675–1685PubMedCrossRefGoogle Scholar
  92. 92.
    Trottier V, Namias N, Pust DG, Nuwayhid Z, Manning R, Marttos AC Jr, Dunham MB, Schulman CI, McKenney MG (2007) Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 8:437–443CrossRefGoogle Scholar
  93. 93.
    Magnotti LJ, Croce MA, Zarzaur BL, Swanson JM, Wood GC, Weinberg JA, Fabian TC (2011) Causative pathogen dictates optimal duration of antimicrobial therapy for ventilator-associated pneumonia in trauma patients. J Am Coll Surg 212:476–484PubMedCrossRefGoogle Scholar
  94. 94.
    Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK (2013) Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 144:1759–1767PubMedCrossRefGoogle Scholar
  95. 95.
    Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group (2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588–2598PubMedCrossRefGoogle Scholar
  96. 96.
    Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME (2005) Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9(1):R53–R59PubMedCentralPubMedCrossRefGoogle Scholar
  97. 97.
    Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME (2008) Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 102:407–412PubMedCrossRefGoogle Scholar
  98. 98.
    Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM (2010) Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 43:323–331PubMedCrossRefGoogle Scholar
  99. 99.
    Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S (2011) Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva 35:226–231PubMedCrossRefGoogle Scholar
  100. 100.
    Arnold HM, Sawyer AM, Kollef MH (2012) Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care. 57(8):1226–1233PubMedCrossRefGoogle Scholar
  101. 101.
    Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G (2010) Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case–control study. Clin Infect Dis 51:1238–1244PubMedCrossRefGoogle Scholar
  102. 102.
    Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V (2010) Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother 65:2645–2649PubMedCrossRefGoogle Scholar
  103. 103.
    Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, Spanu T, Antonelli M (2013) Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144:1768–1775PubMedCrossRefGoogle Scholar
  104. 104.
    Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized Antibiotics Study Group (2012) Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117:1335–1347PubMedCrossRefGoogle Scholar
  105. 105.
    Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, Crookes B, Schulman CI (2007) Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 8:73–82CrossRefGoogle Scholar
  106. 106.
    Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J (2009) Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 13(6):R200PubMedCentralPubMedCrossRefGoogle Scholar
  107. 107.
    Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS (2012) BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 38:263–271PubMedCrossRefGoogle Scholar
  108. 108.
    Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ (2012) Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38:1779–1786PubMedCrossRefGoogle Scholar
  109. 109.
    Hsieh TC, Chen FL, Ou TY, Jean SS, Lee WS (2014) Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization. J Microbiol Immunol Infect. doi: 10.1016/j.jmii.2014.08.009 (Epub ahead of print) Google Scholar
  110. 110.
    Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S, Alamanos I et al (2009) Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 53:4907–4910PubMedCentralPubMedCrossRefGoogle Scholar
  111. 111.
    Ziaka M, Markantonis SL, Fousteri M, Zygoulis P, Panidis D, Karvouniaris M, Makris D, Zakynthinos E (2013) Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother 57:1938–1940PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Karaiskos I, Galani L, Baziaka F, Giamarellou H (2013) Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents 41:499–508PubMedCrossRefGoogle Scholar
  113. 113.
    Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39:1267–1284PubMedCrossRefGoogle Scholar
  114. 114.
    Karaiskos I, Galani L, Baziaka F, Katsouda E, Ioannidis I, Andreou A, Paskalis H, Giamarellou H (2013) Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. Int J Antimicrob Agents 41:480–483PubMedCrossRefGoogle Scholar
  115. 115.
    Guardado AR, Blanco A, Asensi V, Pérez F, Rial JC, Pintado V, Bustillo E, Lantero M, Tenza E, Alvarez M, Maradona JA, Cartón JA (2008) Multidrug-resistant acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 61:908–913CrossRefGoogle Scholar
  116. 116.
    Rosenbaum P et al Guide to the elimination of multidrug-resistant Acinetobacter baumannii transmission in healthcare settings. An APIC guide 2010.
  117. 117.
    Villegas MV, Hartstein AI (2003) Acinetobacter outbreaks 1977–2000. Infect Control Hosp Epidemiol 24(4):284–295PubMedCrossRefGoogle Scholar
  118. 118.
    Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, Garnacho-Montero J, Cisneros JM, Ortíz C, Pachón J, Aznar J (2009) Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 30:257–263PubMedCrossRefGoogle Scholar
  119. 119.
    Fierobe L, Lucet JC, Decré D, Muller-Serieys C, Deleuze A, Joly-Guillou ML, Mantz J, Desmonts JM (2001) An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 22:35–40PubMedCrossRefGoogle Scholar
  120. 120.
    Monterrubio-Villar J, González-Velasco C, Valdezate-Ramos S, Córdoba-López A, Villalón-Panzano P, Saéz-Nieto JA (2009) Outbreak of multiresistant Acinetobacter baumannii in a polyvalent intensive care unit: clinical, epidemiological analysis and PFGE-printing evolution. Eur J Clin Microbiol Infect Dis 28:1281–1284PubMedCrossRefGoogle Scholar
  121. 121.
    Otter JA, Yezli S, Schouten MA, van Zanten AR, Houmes-Zielman G, Nohlmans-Paulssen MK (2010) Hydrogen peroxide vapor decontamination of an intensive care unit to remove environmental reservoirs of multidrug-resistant gram-negative rods during an outbreak. Am J Infect Control 38:754–756PubMedCrossRefGoogle Scholar
  122. 122.
    Barbut F, Yezli S, Mimoun M, Pham J, Chaouat M, Otter JA (2013) Reducing the spread of Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus on a burns unit through the intervention of an infection control bundle. Burns 39:395–403PubMedCrossRefGoogle Scholar
  123. 123.
    Rebmann T, Rosenbaum PA (2011) Preventing the transmission of multidrug-resistant Acinetobacter baumannii: an executive summary of the association for professionals in infection control and epidemiology's elimination guide. Am J Infect Control 39:439–441PubMedCrossRefGoogle Scholar
  124. 124.
    Fournier PE, Richet H (2006) The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42:692–699PubMedCrossRefGoogle Scholar
  125. 125.
    Rebmann T, Rosenbaum PA (2011) Preventing the transmission of multidrug-resistant Acinetobacter baumannii: an executive summary of the association for professionals in infection control and epidemiology's elimination guide. Am J Infect Control 39:439–441PubMedCrossRefGoogle Scholar
  126. 126.
    Young LS, Sabel AL, Price CS (2007) Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 28(1):247–254Google Scholar
  127. 127.
    Denton M, Wilcox MH, Parnell P et al (2004) Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. J Hosp Infect 56:106–110PubMedCrossRefGoogle Scholar
  128. 128.
    Doidge M, Allworth AM, Woods M, Marshall P, Terry M, O'Brien K, Goh HM, George N, Nimmo GR, Schembri MA, Lipman J, Paterson DL (2010) Control of an outbreak of carbapenem-resistant Acinetobacter baumannii in Australia after introduction of environmental cleaning with a commercial oxidizing disinfectant. Infect Control Hosp Epidemiol 31:418–420PubMedCrossRefGoogle Scholar
  129. 129.
    Barnes SL, Morgan DJ, Harris AD, Carling PC, Thom KA (2014) Preventing the transmission of multidrug-resistant organisms: modeling the relative importance of hand hygiene and environmental cleaning interventions. Infect Control Hosp Epidemiol 35:1156–1162PubMedCentralPubMedCrossRefGoogle Scholar
  130. 130.
    Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, Kahlmeter G, Pan A, Petrosillo N, Rodríguez-Baño J, Singh N, Venditti M, Yokoe DS, Cookson B, European Society of Clinical Microbiology (2014) ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20(Suppl 1):1–55PubMedCrossRefGoogle Scholar
  131. 131.
    Marchaim D, Navon-Venezia S, Schwartz D, Tarabeia J, Fefer I, Schwaber MJ, Carmeli Y (2007) Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol 45:1551–1555PubMedCentralPubMedCrossRefGoogle Scholar
  132. 132.
    Ayats J, Corbella X, Ardanuy C, Domínguez MA, Ricart A, Ariza J, Martin R, Liñares J (1997) Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect 37:287–295PubMedCrossRefGoogle Scholar
  133. 133.
    Gordon NC, Wareham DW (2009) Evaluation of CHROMagar Acinetobacter for detection of enteric carriage of multidrug-resistant Acinetobacter baumannii in samples from critically ill patients. J Clin Microbiol 47:2249–2251PubMedCentralPubMedCrossRefGoogle Scholar
  134. 134.
    Ajao AO, Robinson G, Lee MS, Ranke TD, Venezia RA, Furuno JP, Harris AD, Johnson JK (2011) Comparison of culture media for detection of Acinetobacter baumannii in surveillance cultures of critically-ill patients. Eur J Clin Microbiol Infect Dis 30:1425–1430PubMedCentralPubMedCrossRefGoogle Scholar
  135. 135.
    Corbella X, Pujol M, Argerich MJ, Ayats J, Sendra M, Peña C, Ariza J (1999) Environmental sampling of Acinetobacter baumannii: moistened swabs versus moistened sterile gauze pads. Infect Control Hosp Epidemiol 20(7):458–460PubMedCrossRefGoogle Scholar
  136. 136.
    Chang HL, Tang CH, Hsu YM, Wan L, Chang YF, Lin CT, Tseng YR, Lin YJ, Sheu JJ, Lin CW, Chang YC, Ho MW, Lin CD, Ho CM, Lai CH (2009) Nosocomial outbreak of infection with multidrug-resistant Acinetobacter baumannii in a medical center in Taiwan. Infect Control Hosp Epidemiol 30:34–38PubMedCrossRefGoogle Scholar
  137. 137.
    Cristina ML, Spagnolo AM, Ottria G, Sartini M, Orlando P, Perdelli F, Galliera Hospital Group (2011) Spread of multidrug carbapenem-resistant Acinetobacter baumannii in different wards of an Italian hospital. Am J Infect Control 39:790–794PubMedCrossRefGoogle Scholar
  138. 138.
    Carling PC, Parry F, von Beheren M (2008) Identifying opportunities to enhance environmental cleaning in 23 acute care hospitals. Infect Control Hosp Epidemiol 29:1–7PubMedCrossRefGoogle Scholar
  139. 139.
    Manian FA, Griesenauer S, Senkel D, Setzer JM, Doll SA, Perry AM et al (2011) Isolation of Acinetobacter baumannii complex and methicillin-resistant Staphylococcus aureus from hospital rooms following terminal cleaning and disinfection: can we do better? Infect Control Hosp Epidemiol 32:667–672PubMedCrossRefGoogle Scholar
  140. 140.
    La Forgia C, Franke J, Hacek DM, Thomson RB Jr, Robicsek A, Peterson LR (2010) Management of a multidrug-resistant Acinetobacter baumannii outbreak in an intensive care unit using novel environmental disinfection: a 38-month report. Am J Infect Control 38:259–263PubMedCrossRefGoogle Scholar
  141. 141.
    Liu WL, Liang HW, Lee MF, Lin HL, Lin YH, Chen CC, Chang PC, Lai CC, Chuang YC, Tang HJ (2014) The impact of inadequate terminal disinfection on an outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit. PLoS ONE 9(9):e107975PubMedCentralPubMedCrossRefGoogle Scholar
  142. 142.
    Rutala WA, Weber DJ (2013) Disinfectants used for environmental disinfection and new room decontamination technology. Am J Infect Control 41(suppl 5):S36–S41PubMedCrossRefGoogle Scholar
  143. 143.
    Passaretti C, Otter JA, Reich NG et al (2013) An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis 56:27–35PubMedCrossRefGoogle Scholar
  144. 144.
    Ling ML, Ang A, Wee M, Wang GCY (2001) A nosocomial outbreak of multiresistant Acinetobacter baumannii originating from an intensive care unit. Infect Control Hosp Epidemiol 22:48–49PubMedCrossRefGoogle Scholar
  145. 145.
    Fierobe L, Lucet J-C, Decre D et al (2001) An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 22:35–40PubMedCrossRefGoogle Scholar
  146. 146.
    Ayraud-Thévenot S, Huart C, Mimoz O, Taouqi M, Laland C, Bousseau A, Castel O (2012) Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. J Hosp Infect 82:290–292PubMedCrossRefGoogle Scholar
  147. 147.
    Rodríguez-Baño J, García L, Ramírez E, Martínez-Martínez L, Muniain M, Fernández-Cuenca F, Beltrán M, Gálvez J, Rodríguez J, Velasco C et al (2009) Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive “bundle” approach. Am J Infect Control 37:715–722PubMedCentralPubMedCrossRefGoogle Scholar
  148. 148.
    Corbella X, Montero A, Pujol M et al (2000) Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38:4086–4095PubMedCentralPubMedGoogle Scholar
  149. 149.
    Urban C, Segal-Maurer S, Rahal J (2003) Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 36:1268–1274PubMedCrossRefGoogle Scholar
  150. 150.
    Munoz-Price LS, Carling P, Cleary T, Fajardo-Aquino Y, DePascale D, Jimenez A, Hughes M, Namias N, Pizano L, Kett DH, Arheart K (2014) Control of a two-decade endemic situation with carbapenem-resistant Acinetobacter baumannii: electronic dissemination of a bundle of interventions. Am J Infect Control 42:466–471PubMedCrossRefGoogle Scholar
  151. 151.
    Kempf M, Rolain JM, Azza S, Diene S, Joly-Guillou ML, Dubourg G, Colson P, Papazian L, Richet H, Fournier PE, Ribeiro A, Raoult D (2013) Investigation of Acinetobacter baumannii resistance to carbapenems in Marseille hospitals, south of France: a transition from an epidemic to an endemic situation. APMIS 121:64–71PubMedCrossRefGoogle Scholar
  152. 152.
    Bernards AT, Harinck HIJ, Dijkshoorn L, van der Reijden TJK (2004) Persistent Acinetobacter baumannii? Look inside your medical equipment. Infect Control Hosp Epidemiol 25:1002–1004PubMedCrossRefGoogle Scholar
  153. 153.
    Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F et al (2004) Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 25:819–824PubMedCrossRefGoogle Scholar
  154. 154.
    Munoz-Price LS, Arheart K, Nordmann P, Boulanger AE, Cleary T, Alvarez R, Pizano L, Namias N, Kett DH, Poirel L (2013) Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital. Crit Care Med 41:2733–2742PubMedCrossRefGoogle Scholar
  155. 155.
    Apisarnthanarak A, Pinitchai U, Thongphubeth K, Yuekyen C, Warren DK, Fraser VJ (2008) A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. Clin Infect Dis 47:760–767PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2015

Authors and Affiliations

  • José Garnacho-Montero
    • 1
  • George Dimopoulos
    • 2
  • Garyphallia Poulakou
    • 3
  • Murat Akova
    • 4
  • José Miguel Cisneros
    • 5
  • Jan De Waele
    • 6
  • Nicola Petrosillo
    • 7
  • Harald Seifert
    • 8
    • 9
  • Jean François Timsit
    • 10
    • 11
  • Jordi Vila
    • 12
  • Jean-Ralph Zahar
    • 13
  • Matteo Bassetti
    • 14
  1. 1.Unidad Clínica de Cuidados IntensivosInstituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del RocíoSevilleSpain
  2. 2.Department of Critical CareUniversity Hospital ATTIKON, Medical School, University of AthensAthensGreece
  3. 3.4th Department of Internal MedicineAthens University School of Medicine, Attikon University General HospitalAthensGreece
  4. 4.Department of Infectious DiseasesHacettepe University School of MedicineAnkaraTurkey
  5. 5.Unidad Clínicia de Enfermedades Infecciosas, Microbiología y PreventivaInstituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del RocíoSevilleSpain
  6. 6.Department of Critical Care MedicineGhent University HospitalGhentBelgium
  7. 7.2nd Infectious Disease DivisionNational Institute for Infectious Diseases ‘L. Spallanzani’RomeItaly
  8. 8.Institute for Medical Microbiology, Immunology and Hygiene, University of CologneCologneGermany
  9. 9.German Centre for Infection Research (DZIF), Partner Site Bonn-CologneBonnGermany
  10. 10.Medical and Infectious Diseases ICUBichat HospitalParisFrance
  11. 11.University Paris-Diderot - Inserm U1137 - IAMEParisFrance
  12. 12.Department of Clinical Microbiology, CDB, Hospital Clínic, School of MedicineUniversity of Barcelona, Centre for International Health Research, (CRESIB-Hospital Clínic)BarcelonaSpain
  13. 13.Unité de Prévention et de Lutte Contre les Infections NosocomialesUniversité d’Angers, Centre Hospitalo-universitaire d’AngersAngersFrance
  14. 14.Infectious Diseases ClinicSanta Maria Misericordia University HospitalUdineItaly

Personalised recommendations